AbCellera Biologics (ABCL) Revenue: 2019-2024
Historic Revenue for AbCellera Biologics (ABCL) over the last 6 years, with Dec 2024 value amounting to $28.8 million.
- AbCellera Biologics' Revenue fell 57.40% to $9.2 million in Q4 2023 from the same period last year, while for Dec 2023 it was $38.0 million, marking a year-over-year decrease of 92.17%. This contributed to the annual value of $28.8 million for FY2024, which is 24.17% down from last year.
- Latest data reveals that AbCellera Biologics reported Revenue of $28.8 million as of FY2024, which was down 24.17% from $38.0 million recorded in FY2023.
- AbCellera Biologics' 5-year Revenue high stood at $485.4 million for FY2022, and its period low was $28.8 million during FY2024.
- Its 3-year average for Revenue is $184.1 million, with a median of $38.0 million in 2023.
- Per our database at Business Quant, AbCellera Biologics' Revenue spiked by 1,907.88% in 2020 and then slumped by 92.17% in 2023.
- Over the past 5 years, AbCellera Biologics' Revenue (Yearly) stood at $233.2 million in 2020, then surged by 60.92% to $375.2 million in 2021, then grew by 29.38% to $485.4 million in 2022, then tumbled by 92.17% to $38.0 million in 2023, then dropped by 24.17% to $28.8 million in 2024.